IBBJ
Small Cap Biotech ETF
Because Juniors Grow
Covid vaccines, cancer treatments, R&D for a healthier future. IBBJ captures the next gen strength of biotech and pharma in the space with greatest growth potential – small cap companies with big ideas.
IBBJ offers the investor liquid, transparent and low-cost* access to junior companies that are classified as either biotechnology or pharmaceutical. The ETF can be traded intraday, providing flexible yet targeted exposure to a potentially growing sector.
The underlying Nasdaq Junior Biotechnology Index tracks approximately 241 companies from over 16 countries.
The Nasdaq Junior Biotechnology Index is a modified market capitalization weighted index that tracks the performance of small-cap “junior” companies listed on the Nasdaq Stock Market® (Nasdaq®), which are under $5 billion of market capitalization. They must be classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
These are companies engaged in biotech research and development, the sale or licensing of biological substances for the purposes of drug discovery and diagnostic development; and pharmaceutical manufacturers of prescription or over-the counter drugs, including vaccines and development and manufacturing companies.
Why Invest In Junior Biotech?
Junior biotech companies, with a market capitalization that is less than $5 billion, have the potential advantage of a Food and Drug Administration more receptive to new cutting-edge and rare-disease therapies. They are possibly also strengthened by increased patient lobbying and greater willingness by insurers to pay for treatments. Combined with the potential for mergers-and-acquisitions and the U.S. government’s recent gigantic Covid-19 aid to small and mid-sized companies, small-caps seemed likely to lead the domestic recovery.
The value of the global pharmaceutical market rose from about US$390 billion in 2001, to about US$1.25 trillion at the end of 2019.1
Whether for cancer research, or a vaccine or treatment for Covid-19, we believe the strong demand side continues to combine with government regulation and policies prioritizing these sectors.
In uncertain and unpredictable times, biotechnology benchmarks have been known to beat the wider market.2
—
1 “Revenue of the worldwide pharmaceutical market from 2001 to 2019,” Statista, https://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001/
2 “Biotech ETFs in the Spotlight, Why They’ll Remain There,” Tom Lydon, ETF Trends, June 18, 2020, https://www.etftrends.com/etf-building-blocks-channel/biotech-etfs-in-the-spotlight-why-they-can-remain-there/
* Commissions may be charged on trades.
Fund Data and Pricing
Fund Details
| YTD | 1 Months | 3 Months | 6 Months | 1 Year | Since Inception | |
|---|---|---|---|---|---|---|
| Total Return (%) | 4.54% | 0.62% | 16.06% | 43.08% | xx.xx% | 45.20% |
| Market Price (%) | 4.76% | 1.06% | 16.63% | 43.15% | xx.xx% | 45.58% |
| 1 Year | Since Inception | |
|---|---|---|
| Total Return (%) | xx.xx% | xx.xx% |
| Market Price (%) | xx.xx% | xx.xx% |
| YTD | 1 Months | 3 Months | 6 Months | 1 Year | Since Inception | |
|---|---|---|---|---|---|---|
| Total Return (%) | xx.xx% | 2.48% | xx.xx% | xx.xx% | xx.xx% | 4.01% |
| Market Price (%) | xx.xx% | 2.21% | xx.xx% | xx.xx% | xx.xx% | 3.94% |
| 1 Year | Since Inception | |
|---|---|---|
| Total Return (%) | xx.xx% | xx.xx% |
| Market Price (%) | xx.xx% | xx.xx% |
| YTD | 1 Months | 3 Months | 6 Months | 1 Year | Since Inception | |
|---|---|---|---|---|---|---|
| Total Return (%) | xx.xx% | 14.62% | 23.28% | xx.xx% | xx.xx% | 25.11% |
| Market Price (%) | xx.xx% | 14.78% | 22.74% | xx.xx% | xx.xx% | 24.82% |
| 1 Year | Since Inception | |
|---|---|---|
| Total Return (%) | xx.xx% | xx.xx% |
| Market Price (%) | xx.xx% | xx.xx% |
| YTD | 1 Months | 3 Months | 6 Months | 1 Year | Since Inception | |
|---|---|---|---|---|---|---|
| Total Return (%) | 3.90% | 3.90% | 32.21% | xx.xx% | xx.xx% | 44.31% |
| Market Price (%) | 3.66% | 3.66% | 32.45% | xx.xx% | xx.xx% | 44.04% |
| 1 Year | Since Inception | |
|---|---|---|
| Total Return (%) | xx.xx% | xx.xx% |
| Market Price (%) | xx.xx% | xx.xx% |
| YTD | 1 Months | 3 Months | 6 Months | 1 Year | Since Inception | |
|---|---|---|---|---|---|---|
| Total Return (%) | xx.xx% | xx.xx% | xx.xx% | xx.xx% | xx.xx% | 1.49% |
| Market Price (%) | xx.xx% | xx.xx% | xx.xx% | xx.xx% | xx.xx% | 1.69% |
| 1 Year | Since Inception | |
|---|---|---|
| Total Return (%) | xx.xx% | xx.xx% |
| Market Price (%) | xx.xx% | xx.xx% |
| YTD | 1 Months | 3 Months | 6 Months | 1 Year | Since Inception | |
|---|---|---|---|---|---|---|
| Total Return (%) | xx.xx% | 4.95% | xx.xx% | xx.xx% | xx.xx% | 9.15% |
| Market Price (%) | xx.xx% | 4.63% | xx.xx% | xx.xx% | xx.xx% | 8.75% |
| 1 Year | Since Inception | |
|---|---|---|
| Total Return (%) | xx.xx% | xx.xx% |
| Market Price (%) | xx.xx% | xx.xx% |
| YTD | 1 Months | 3 Months | 6 Months | 1 Year | Since Inception | |
|---|---|---|---|---|---|---|
| Total Return (%) | xx.xx% | 11.02% | 33.55% | xx.xx% | xx.xx% | 38.90% |
| Market Price (%) | xx.xx% | 11.33% | 33.69% | xx.xx% | xx.xx% | 38.96% |
| 1 Year | Since Inception | |
|---|---|---|
| Total Return (%) | xx.xx% | xx.xx% |
| Market Price (%) | xx.xx% | xx.xx% |
| 2020 | |
|---|---|
| Total Return (%) | xx.xx% |
| Market Price (%) | xx.xx% |
| Name | Symbol | Stock price | % Net assets | Shares Held | Market Value | |
|---|---|---|---|---|---|---|
|
Bridgebio Pharma Inc | BBIO | $62.22 | 3.24% | 4,400 | 273,768 |
|
Zai Lab Ltd | ZLAB | $137.25 | 2.05% | 1,265 | 173,621 |
|
Fate Therapeutics Inc | FATE | $83.65 | 1.95% | 1,975 | 165,209 |
|
Allakos Inc | ALLK | $123.73 | 1.74% | 1,190 | 147,239 |
|
Gw Pharmaceuticals Plc | GWPH | $214.94 | 1.74% | 685 | 147,234 |
|
Kodiak Sciences Inc | KOD | $120.49 | 1.64% | 1,150 | 138,564 |
|
Vir Biotechnology Inc | VIR | $45.18 | 1.54% | 2,890 | 130,570 |
|
Medpace Hldgs Inc | MEDP | $157.54 | 1.52% | 815 | 128,395 |
|
Halozyme Therapeutics Inc | HALO | $40.91 | 1.49% | 3,070 | 125,594 |
|
Pacific Biosciences Calif Inc Com | PACB | $29.27 | 1.47% | 4,245 | 124,251 |
| Download Fund Documents |
|---|
 |
 |
 |
 |
 |
 |
 |
 |
 |
Distribution
| Ex-Date | Total Distribution |
|---|---|
| 12/29/2020 | $0.29981 |
| 03/24/2021 | xx.xx |
Download Distribution Schedule
 |
|
Reasons to invest in IBBJ
Performance.
The record shows junior biotech stocks beating their senior counterparts over the last six months.
US leads in global pharma innovation.
Strong R&D budgets bring results. The US produced almost half of all biotech patents filed from 1999 to 2013.
Large cap pharma firms cash heavy and looking to invest.
The ten largest biotech/pharma companies in the S&P 500 had an average cash stockpile of $10.7 billion as of mid-June, 2020.
Patent cliff.
Pharma giants look for new revenue flows as their exclusive rights to existing patents dwindle.
